

ForPatients

by Roche

Breast Cancer Er-Positive Breast Cancer HER-2 Negative Locally Advanced or Metastatic Breast Cancer Breast Cancer Estrogen Receptor (ER)-Positive

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Trial Status

Active, not recruiting

Trial Runs In

13 Countries

Trial Identifier

NCT05306340

2022-000199-20,2023-506821-12-00

ML43171

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

Genentech, Inc.

Sponsor

Phase 3

Phase

NCT05306340 2022-000199-20,2023-506821-12-00 ML43171

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No